First HIV case detected in India
Dr Suniti Solomon identifies India's first confirmed HIV case among sex workers in Chennai, marking the start of the Indian epidemic.
India averted a generalised HIV epidemic that experts had feared would reach 20 million by 2010. How it happened, what the data shows, and why 2.4 million Indians living with HIV still face.
Audio version coming soon
India's HIV trajectory is one of the great quiet public health wins of the past two decades. UNAIDS and NACO estimates show people living with HIV in India falling from a peak of around 5.1 million in the late 1990s to about 2.4 million in 2024. New annual infections have dropped by close to 48 percent since 2010 and AIDS-related deaths by about 79 percent. Targeted prevention with key populations including sex workers, men who have sex with men, transgender persons and people who inject drugs through the National AIDS Control Programme and the Gates Foundation-supported Avahan kept HIV concentrated and prevented the generalised explosion that engulfed parts of Africa. Free antiretroviral therapy since 2004 added a treatment backbone. But the epidemic is not over. Around 60 to 70 thousand new infections occur each year, stigma remains intense, and treatment continuity, viral load testing and care for adolescents living with HIV are still uneven across states.
India's success rested on four pillars. First, the National AIDS Control Programme adopted a targeted intervention model focused on key populations and high-risk corridors rather than mass campaigns alone. Outreach by peer educators and the Targeted Intervention NGOs delivered condoms, syringes and harm reduction where they were needed most. Second, the Gates Foundation-supported Avahan project in six high-prevalence states between 2003 and 2013 invested over 400 million dollars to scale up clinics, condom supply and structural interventions like crisis response and rights protection for sex workers. Third, free first-line antiretroviral therapy from 2004 onwards, expanded to second-line in 2008 and third-line in 2017, kept viral loads down and reduced onward transmission. Fourth, prevention of parent-to-child transmission programmes and a steady scale-up of HIV testing, including community testing in priority districts, cut new infant infections. These efforts together moved India from a feared explosion to a manageable concentrated epidemic.
Unread picks stay on top. Fresh stories may appear as they are ready โ no extra loading.
India now has 12 million obese children under 19, according to ICMR data. School canteens sell junk food while ultra-processed food advertising targets children.
India collects only 11 million units of blood annually against a need of 15 million. The O-negative shortage is acute, urban blood banks run on single-day reserves, and the rural gap is catastrophic.
India has fewer sports medicine doctors than many US college programs. Cricket and marathons grew fast; specialist care did not, so preventable injuries end careers early.
Biosimilars โ cheaper copies of complex biological drugs โ are worth 50 billion globally. Indian companies are racing to capture that market, threatening to cut the price of cancer and.
Micronutrient gaps hit rich and poor: anaemia stays high, vegetarians often lack B12, and urban adults lack vitamin D. Fortification and better diets can bend the curve if delivery improves.
127 essential medicines are out of stock in government hospitals across 12 states. The shortage hits insulin, antibiotics and cancer drugs. Central procurement failure exposes PM Jan Aushadhi gaps.
Key statistics on HIV in India:
Myth 1: HIV can be caught from sharing food, water or a toilet. Fact: HIV is spread only through specific routes, unprotected sex, blood, sharing needles, and mother to child during pregnancy, birth or breastfeeding. Sharing utensils, hugging, casual contact and mosquito bites do not transmit HIV. This myth still drives much of the social rejection of HIV-positive Indians.
Myth 2: Modern ART means HIV is no longer dangerous and condoms are unnecessary. Fact: ART is a powerful tool. People on suppressive therapy can have normal life expectancy and undetectable patients do not transmit sexually. But ART does not cure HIV, it must be taken for life, and condoms still prevent other STIs and unwanted pregnancy. Drug interruption and rising rates of resistance in some Indian cohorts are real concerns.
Myth 3: HIV is a problem only of certain communities. Fact: Key populations carry higher risk, but a significant share of new infections in India now occurs through long-term partners and stable relationships, especially after one partner becomes infected during migration for work. Routine testing of pregnant women, partners and people with TB is essential, and HIV literacy is everyone's concern.
Take Suresh Kamble, a 36-year-old construction worker in Mumbai diagnosed with HIV in 2010 during a routine pre-employment test. With free first-line ART from a NACO ART centre, he is now virally suppressed, married with two HIV-negative children born under PPTCT, and saving for a small house. His story has become common, but stigma still costs him sleep. He has never told his employer and avoids workplace health camps. Across India, ART now saves lives and the legal protection of the HIV AIDS Act 2017 is real, but enforcement is weak. Women living with HIV in north Indian families still face property disputes and forced separation, and adolescents born with HIV often struggle to disclose status when entering relationships. The economic burden of fixed wages of those on ART is lower than fifteen years ago. The remaining costs are travel to ART centres, occasional opportunistic infection care and the silent tax of secrecy.
The bigger meaning of India's HIV journey is that focused, evidence-based prevention with key populations, paired with generic ART and rights-based legislation, can hold back a global pandemic at scale. The long-term consequence is millions of Indians who would otherwise have died are alive and the country avoided a development-shattering generalised epidemic. The lesson is that the gains are real but fragile. Without sustained funding, key population programmes can shrink, drug supply can wobble and stigma will fill the gap. India's future depends on closing the remaining 24 percent gap in those on ART, scaling up self-testing, expanding PrEP to high-risk populations, integrating HIV care with TB and mental health services, and protecting the HIV AIDS Act in practice. India is also the world's pharmacy for affordable antiretrovirals, so the country's choices on patents, exports and innovation will shape what HIV treatment looks like across the Global South in the next decade.
Chronology
Follow the arc from background to turning points. On mobile, swipe the cards and use the step rail below; on desktop, use the spine to jump.
Dr Suniti Solomon identifies India's first confirmed HIV case among sex workers in Chennai, marking the start of the Indian epidemic.
India launches NACP-I with World Bank support, focusing on awareness, blood safety and basic surveillance.
Bill and Melinda Gates Foundation launches Avahan, a 400 million dollar HIV prevention programme focused on key populations in six high-prevalence states.
NACO starts free first-line antiretroviral therapy in eight high-prevalence states, eventually expanding nationwide and becoming a treatment backbone.
UNAIDS adopts the 90-90-90 targets for diagnosis, treatment and viral suppression, against which India tracks its progress through the rest of the decade.
India enacts the HIV AIDS Prevention and Control Act 2017, prohibiting discrimination, ensuring informed consent and recognising rights to treatment.
UNAIDS and NACO confirm India's people-living-with-HIV count at around 2.4 million, with 79 percent diagnosed and 76 percent on treatment.
Step 1/7 events
Understand why it happened, how we got here, and what might come next.